Blood Markers to Predict AML Treatment Response
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at special markers in bone marrow fluid to predict how well chemotherapy will work for newly diagnosed acute myeloid leukemia (AML). By identifying these markers early, doctors may be able to choose the best treatment plan for each patient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Newly diagnosed with acute myeloid leukemia (AML), not a type called APL
- Have never received chemotherapy before for this disease
- Have a family member who can participate with you in the study
- Able to understand the study and sign consent documents
- No other active cancers requiring treatment
- No serious infections like HIV, hepatitis, or COVID-19
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at a substance called leptin in the blood of people with newly diagnosed acute myeloid leukemia (AML). The goal is to see if leptin levels can help doctors predict how well chemotherapy will work, which could guide better treatment choices.
This trial studies whether the levels of certain proteins and blood clotting factors in your blood can help doctors understand acute myeloid leukemia better. It may lead to better ways to monitor the disease and its effects on your body.
This study looks at whether certain blood test levels (ferritin, and two ratios called CAR and AFR) can help predict how patients with a type of leukemia called AML (non-M3) will do. The goal is to find clues that may guide future treatment decisions.
This trial looks at certain chemical changes in blood cells of two groups of people aged 60 or older: those having heart surgery (control group) and those with a type of blood cancer called acute myeloid leukemia (AML) who will be treated with a drug called azacitidine. The goal is to find markers that could help personalize treatment for AML in seniors.
This study looks at certain proteins in the blood (called FLT3 ligand and IL6) of people being treated for blood cancers like AML, MDS, or CMML. The goal is to understand how these proteins change during non-intensive chemotherapy, which may help doctors better personalize treatment.
This study uses a special blood test to see if it can predict which patients with a specific type of acute myeloid leukemia (AML with MLL changes) are more likely to relapse or have better survival. The test may help doctors plan better treatment.
Hear when a new Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.